10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal

Author： Kurnik Daniel   Loebstein Ronen   Halkin Hillel   Gak Eva   Almog Shlomo  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.10, Iss.12, 2009-12, pp. : 1955-1965

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenomics – 10 years of progress: a cardiovascular perspective

By Winkelmann Bernhard R   Herrington David  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 613-616

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics in anticoagulant drug development

By Iqbal Omer  

Pharmacogenomics, Vol. 3, Iss. 6, 2002-11 ,pp. : 823-828

Future Medicine

Access to resources Recommend Favorite

Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients

By Di Minno Matteo Nicola Dario  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 1, 2013-03 ,pp. : 9-23

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of Oral Anticoagulant Therapy

By  

Current Pharmaceutical Design, Vol. 16, Iss. 2, 2010-01 ,pp. : 187-203

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenomics of Oral Antithrombotic Drugs

By  

Current Pharmaceutical Design, Vol. 22, Iss. 13, 2016-04 ,pp. : 1933-1949

Bentham Science Publishers

Access to resources Recommend Favorite